Adage Capital Partners’s Edgewise Therapeutics EWTX Stock Holding History

Adage Capital Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.8M	Buy	+462,000	New	+$15.9M	0.03%	512
2025 Q2	–	Sell	-390,000	Closed	-$8.58M	–	882
2025 Q1	$8.58M	Buy	390,000 +150,000	+63%	+$3.94M	0.02%	616
2024 Q4	$6.41M	Buy	240,000 +218,491	+1,016%	+$6.96M	0.01%	686
2024 Q3	$574K	Sell	21,509 -28,088	-57%	-$559K	﹤0.01%	810
2024 Q2	$893K	Buy	+49,597	New	+$865K	﹤0.01%	806
2021 Q2	–	Sell	-300,000	Closed	-$9.75M	–	1030
2021 Q1	$9.75M	Buy	+300,000	New	+$9.73M	0.02%	687

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners's EWTX Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 462,000 shares worth $18.8M. The stake represents 0.03% of the portfolio and ranks #512 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in EWTX as recently as Q1 2025.

Adage Capital Partners first reported a position in EWTX in Q1 2021 and has held it in 6 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Adage Capital Partners held 462,000 shares of Edgewise Therapeutics worth $18.8M as of Q2 2026.
Edgewise Therapeutics was a new Adage Capital Partners position in Q2 2026.
Edgewise Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #512 holding.
Adage Capital Partners first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 6 quarters since.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.